Market news — every asset we track

Assets

DSGN

Design Therapeutics at Cantor conference: biomarker push takes center stage

Sep 9Investing.com

Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch

An EV maker on the rebound, a Sun Belt landlord facing fresh headwinds, and a clinical-stage biotech sitting on pivotal pipeline data have all landed on analysts' radars this week for very different reasons.

Aug 27Yahoo Finance

DSGN

Design Therapeutics posts Q2 loss, updates clinical trials

Aug 3Investing.com

DSGN

Design Therapeutics Q2 Net Loss Narrows

Design Therapeutics (DSGN) reported a Q2 net loss late Monday of $0.32 per diluted share, narrowing

Aug 3Yahoo Finance

DSGN

Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results

RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027

Aug 3Barchart.com

DSGN

A Deeper Dive Into Design Therapeutics (NASDAQ:DSGN)

Jul 27Seeking Alpha

DSGN

LRMR

This is the newest page. Registered accounts read further back.